Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Burixafor

            Therapeutic Area: Immunology Product Name: TG-0054

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: GPCR Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 09, 2020


            Under the terms of the agreement, GPCR Therapeutics will be wholly responsible for the development, registration, and commercialization of Taigexyn® in S. Korea and Burixafor worldwide.